Results 141 to 150 of about 1,247,370 (242)

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Analytical and Clinical Validation of Solo-Test Driver: A Targeted Amplicon-Based NGS Test-System for FFPE and cfDNA Analysis in Clinical Oncology Setting. [PDF]

J Clin Lab Anal
Ivanov M, Lebedeva A, Belova E, Grigoreva T, Veselovsky E, Kavun A, Taraskina A, Kuznetsova O, Nikulin V, Belyaeva L, Kravchuk D, Lisitsa T, Barinov A, Pospekhova N, Aliyarova S, Khomenko E, Tryakin A, Demidova I, Stroganova A, Fedyanin M, Mileyko V.   +20 more
europepmc   +1 more source

Editorial: Bridging quantitative imaging and artificial intelligence methods in preclinical and clinical oncology. [PDF]

Front Oncol, 2023
Jansen JF, Paudyal R, Mazaheri Y, Shukla-Dave A.   +3 more
europepmc   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. [PDF]

Int J Clin Oncol
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, Horinouchi H, Ozaki Y, Iwata H, Kato T, Miyake H, Ohba A, Ikeda M, Chiyoda T, Hasegawa K, Fujisawa T, Matsuura K, Namikawa K, Yajima S, Yoshino T, Hasegawa K.   +20 more
europepmc   +1 more source

Editorial: Application and innovation of multiomics technologies in clinical oncology. [PDF]

Front Oncol, 2023
Li X, Budzin A, Wang Y.
europepmc   +1 more source

CINs of the cytoplasm: dissecting dsRNA signaling in chromosomal instability

Molecular Oncology, EarlyView.
Micronuclei, formed during cell division in chromosomal instability settings, rupture and lead to the accumulation of immunogenic double‐stranded RNA in the cytoplasm, activating MAVS‐dependent interferon signaling and innate antitumor immunity.
Aglaia Skolariki, Rose L. Jady‐Clark, Eileen E. Parkes   +2 more
wiley   +1 more source

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update. [PDF]

Cancer Commun (Lond)
Wang F, Chen G, Zhang Z, Yuan Y, Wang Y, Gao YH, Sheng W, Wang Z, Li X, Yuan X, Cai S, Ren L, Liu Y, Xu J, Zhang Y, Liang H, Wang X, Zhou A, Ying J, Li G, Cai M, Ji G, Li T, Wang J, Hu H, Nan K, Wang L, Zhang S, Li J, Xu RH.   +29 more
europepmc   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Competing risks data in clinical oncology. [PDF]

Front Oncol
Kim HT.
europepmc   +1 more source